Paper Details

  1. Home
  2. Paper Details

Drug design strategies for Cushing's syndrome.

Author: KliuchenovichA V, StrushkevichN V, UsanovS A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article discusses recent drug developments for the medical treatment of Cushing's syndrome (CS), focusing on selective inhibitors of CYP11B1 and glucocorticoid receptor (GR) antagonists. The article highlights the unmet need for new compounds that target these pathways selectively.
Paper Details　
Original Abstract of the Article :
Cushing's syndrome (CS) is a metabolic disorder caused by chronic hypercortisolism. CS is associated with cardiovascular, metabolic, skeletal and psychological dysfunctions and can be fatal if left untreated. The first-line treatment for all forms of CS is a surgery. However, medical therapy has to ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/17460441.2019.1559146

データ提供：米国国立医学図書館（NLM）

Cushing's Syndrome: A Search for Effective Treatments

Cushing's syndrome (CS) is a metabolic disorder caused by chronic hypercortisolism, leading to a variety of health problems. The primary treatment for CS is surgery, but medical therapy is necessary when surgery is not an option or ineffective. This review explores recent drug developments for the medical treatment of CS, focusing on two molecular targets: selective inhibitors of CYP11B1, which reduce cortisol production, and glucocorticoid receptor (GR) antagonists, which block cortisol-mediated gene regulation.

Developing Novel Therapeutics: A Quest for Better Treatment Options

This review highlights the urgent need for new and improved treatments for CS. Current therapies often lack selectivity and have side effects, creating a significant unmet need for more effective and well-tolerated medications. This research is like a camel searching for a hidden oasis, seeking a better solution to a challenging health problem. The development of new drugs targeting CYP11B1 or GR signaling pathways could revolutionize the management of CS and improve the lives of affected patients.

A Journey Towards Improved Treatment: Hope on the Horizon

This review offers a glimpse of hope for patients with CS. The development of selective inhibitors of CYP11B1 and GR antagonists holds promise for more effective and targeted treatments. These novel therapies, like a refreshing spring in the desert, could alleviate the symptoms of CS and improve patients' quality of life. Continued research and development are essential for finding the optimal treatment options and ensuring better outcomes for patients with CS.

Dr. Camel's Conclusion

This review highlights the challenges and opportunities in the treatment of Cushing's syndrome. It's like a camel navigating a complex desert landscape, seeking the right path to better health. Continued research and development of new therapies are crucial for improving the lives of patients with CS and providing them with more effective and well-tolerated treatment options.
Date :
  1. Date Completed 2020-03-03
  2. Date Revised 2020-03-03
Further Info :

Pubmed ID

30572739

DOI: Digital Object Identifier

10.1080/17460441.2019.1559146

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.